Evidence-based·Last reviewed May 30, 2026·How we grade evidence

PT-141 (Bremelanotide)

PeptidePeptide drug

Useful mainly for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).

Prescription medication — not a dietary supplement

This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only — it is not a recommendation to obtain or use it without a doctor.

Quick decision guide

May help most

Premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)

Common dosing range

1.75 mg subcutaneously as needed, at least 45 minutes before anticipated sexual activity

When to expect effects

On-demand; taken before activity, with benefit judged over weeks of use

Watch out for

Transient rise in blood pressure; contraindicated in uncontrolled hypertension or known cardiovascular disease

What is it

PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist (acting mainly at MC4R in the central nervous system) given by on-demand subcutaneous injection. Unlike vascular drugs, it works through brain pathways involved in sexual desire and arousal. It is FDA-approved to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You are a premenopausal woman with acquired, generalized HSDD (low desire causing distress, not due to another medical, psychiatric, or relationship cause or a medication)
You prefer an on-demand option and can self-administer subcutaneous injection
Your blood pressure is controlled and you have no significant cardiovascular disease

Probably skip if…

Your low desire stems from a co-existing medical/psychiatric condition, relationship problem, or a medication's side effect
You have uncontrolled hypertension or known cardiovascular disease
You are postmenopausal, pregnant, or seeking it for general libido enhancement outside the indication

Evidence at a glance

hypoactive sexual desire disorder (hsdd) in premenopausal women

Strong Evidence
Effect
Statistically significant improvement in desire score and reduction in desire-related distress versus placebo over 24 weeks
Best fit
Premenopausal women with acquired, generalized HSDD
Time
On-demand; assessed over weeks

Evidence for 1 use

AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.

hypoactive sexual desire disorder (hsdd) in premenopausal women

Disease adjunct
Strong Evidence

Two identical phase-3 randomized, double-blind, placebo-controlled trials (the RECONNECT studies) in premenopausal women with acquired, generalized HSDD showed that on-demand subcutaneous bremelanotide 1.75 mg significantly improved the desire domain score and reduced desire-related distress compared with placebo over 24 weeks. The effect sizes were modest but consistent across both trials and supported FDA approval. About 18% of women discontinued for adverse effects, mainly nausea.

Effect size
Statistically significant improvement in desire score and reduction in desire-related distress versus placebo over 24 weeks
Time to effect
On-demand; assessed over weeks
Best fit
Premenopausal women with acquired, generalized HSDD

Bottom line: On-demand bremelanotide produces a modest but reproducible improvement in sexual desire and distress in premenopausal women with HSDD.

SourceKingsberg et al., 2019 — PMCClayton et al., 2022 — PubMed

How to take it

1. Typical dose
1.75 mg subcutaneously (single autoinjector) on demand, prescribed by a clinician
2. Timing
At least 45 minutes before anticipated sexual activity; no more than one dose per 24 hours and no more than 8 doses per month
3. With food
Independent of food; injected into the abdomen or thigh
4. How long to try
Used on demand; the prescriber discontinues if no improvement after about 8 weeks of use

What to track

Whether desire improves and distress decreases (validated FSFI-desire and FSDS-DAO measures)
Blood pressure response after dosing
Nausea and skin/gum darkening (focal hyperpigmentation)

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

Nausea (common, sometimes requiring antiemetic or discontinuation)FlushingInjection-site reactionsHeadacheVomiting

Serious risks

  • Transient increases in blood pressure and decreases in heart rate after each dose

  • Focal hyperpigmentation (face, gums, breasts), which may not fully resolve, more likely with frequent dosing or darker skin

  • Hypersensitivity reactions

Who should avoid it

  • People with uncontrolled hypertension or known cardiovascular disease
  • People at high cardiovascular risk for whom a transient BP rise is unsafe
  • Pregnant individuals
  • Those who would exceed once-daily / 8-doses-per-month limits

Pregnancy & breastfeeding

Not recommended in pregnancy; discontinue if pregnancy is suspected, as the indication does not apply and safety is not established.

Interactions

Oral naltrexone (and other orally administered drugs)Major

Bremelanotide slows gastric emptying and can significantly reduce absorption of oral naltrexone, risking loss of efficacy for alcohol/opioid use disorder; avoid combination

Antihypertensive medicationsModerate

Bremelanotide transiently raises blood pressure, which can blunt or oppose antihypertensive control

Other slowly absorbed oral drugs taken concurrentlyModerate

Delayed gastric emptying can lower or delay their absorption

Choosing a product

What to look for on the label — and what to be skeptical of.

Look for…

Only obtain via a licensed prescriber and pharmacy as FDA-approved Vyleesi
Supplied as a single-dose prefilled autoinjector for subcutaneous use
Dispensed with counseling on the 45-minute pre-activity timing and monthly dose limit

Be skeptical of…

Grey-market 'PT-141' vials sold as a research peptide or aphrodisiac for either sex
Compounded nasal sprays or unverified peptide blends promising instant libido
Any source marketing it without HSDD diagnosis or a prescription

References by claim

hypoactive sexual desire disorder (hsdd) in premenopausal women

Kingsberg et al., 2019 — PMC (2019) link

Clayton et al., 2022 — PubMed (2022) link

Track PT-141 (Bremelanotide) with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.

Coming to App Store
Evidence-based·Last reviewed May 30, 2026·Evidence current as of May 30, 2026·How we grade evidence

Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.